Eric Viaud, Chairman of the Board, Cofounder and Shareholder
Eric is one of the companyís founders. He is the current CEO of the company. His leadership has successfully brought the company from the drug discovery phase to the current clinical development phases. Eric has a demonstrated track record as a biotech entrepreneur, having successfully overseen and led the development of several Biotech start-up ventures. He is currently an Advisor and Board Member of various biotech companies in Europe. Eric began his career in the Pharmaceuticals Industry and then later moved to Medical Devices. He has held Senior Management positions in the field of sales & marketing, licensing, strategic alliances and R&D. He also has extensive experience in the regulatory & reimbursement fields. Eric holds a Master in Psychology from the University of Bordeaux (France).
Dr. Eric Thorin, Member of the Board, Cofounder and Shareholder
Eric is one of the companyís founders. Eric directs the Companyís drug development work and has successfully steered Gene Signalís leading products through several drug development phases. Eric is a recognized international expert in the field of vascular mechanisms and CVD. He is Associate Professor of Surgery of the Faculty of Medicine of the University of Montreal and a senior researcher at the Montreal Heart Institute. He was formerly Head of Cardiovascular Pharmacology of Actelion Pharmaceuticals (Basel, Switzerland). Eric has received the 1996 Young Investigator Award from the International Society of Hypertension, the 1997 Jonathan Ballon Award of the Quebec Heart & Stroke Foundation and the 1999 MacDonald Award of the Canadian Heart & Stroke Foundation.
Jean Pierre Decker, Member of the Board and Shareholder
Jean Pierre brings more than 20 years of solid experience in general management and business development. He has a solid track- record as an entrepreneur and has successfully founded and developed several start-up operations all over the world. His leadership and management skills have driven long-term growth and profitability and have enabled the successful development of several energy groups.
Antoine Ferry, Member of the Board and Shareholder
Antoine is Gene Signalís Chief Medical Officer responsible for the companyís clinical development strategy. He has played a leading role in the new product development process through successful clinical and regulatory management. Antoine is a biotech entrepreneur with a proven track record in the field of biotechnology. His outstanding work was recognized in 2001 by a National Master Prize (ANVAR 2001). Antoine is also the Board Member of several biotechnology firms. Antoine brings Gene Signal a vast experience in the fields of business development, pharmacology and regulatory. He holds Masters in Clinical Pharmacology, Experimental Pharmacology and Medical Statistics and has over 15 international publications to his name.
Jean CARAUX, M.D. PhD
Jean Caraux M.D. PhD. is a biotech/pharma industry executive with strong, broad and successful experience in the commercialization operations and strategic development of orphan therapies for unmet medical needs, in multiple therapeutic areas. Jean has a proven track record of successful revenue and profit growth in affiliates of US biotechs, in senior positions.
Jean has superior strategic aptitude, deep understanding of key companies and industry trends, as well as a robust knowledge of success factors and environment for innovative therapies development and commercialization. Jeanís scientific and business acumen in a broad set of therapeutic areas, provide him with the maturity to judge the relative potential of competing technologies and therapeutic approaches.
Jean holds M.D and PhD degrees from the Universities of Paris and Montpellier.